Meet the Editorial Board - an interview with Min Meng and transitions from small regional labs to global CRO
Min Meng received her PhD in biomedicinal chemistry from the School of Pharmacy, University of Maryland, in 1996. From 1996 to 1998, Meng was a postdoctoral fellow at the American Health Foundation, focusing on the carcinogenic toxicity of tobacco smoke using various chromatographic technologies such as LC-UV, GC-MS/MS and LC-MS/MS. From 1998 to 2017, Meng worked for Tandem Labs/LabCorp/Covance, a bioanalytical contract research organization (CRO), holding various positions from scientist to lab director and technical director. In 2017, Meng moved back to her hometown and set up a bioanalytical CRO, Denali Medpharma, Chongqing, China. In October 2023, Denali was acquired by Resolian Bioanalytics, a global bioanalytical CRO. Currently, Dr Meng is the chief scientific officer and president of the Asia Pacific region for Resolian Bioanalytics.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Bioanalysis - 16(2024), 2 vom: 01. Jan., Seite 61-64 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Meng, Min [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 22.12.2023 Date Revised 18.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4155/bio-2023-0216 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36457481X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36457481X | ||
| 003 | DE-627 | ||
| 005 | 20240319232334.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/bio-2023-0216 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1336.xml |
| 035 | |a (DE-627)NLM36457481X | ||
| 035 | |a (NLM)37965875 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Meng, Min |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Meet the Editorial Board - an interview with Min Meng and transitions from small regional labs to global CRO |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.12.2023 | ||
| 500 | |a Date Revised 18.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Min Meng received her PhD in biomedicinal chemistry from the School of Pharmacy, University of Maryland, in 1996. From 1996 to 1998, Meng was a postdoctoral fellow at the American Health Foundation, focusing on the carcinogenic toxicity of tobacco smoke using various chromatographic technologies such as LC-UV, GC-MS/MS and LC-MS/MS. From 1998 to 2017, Meng worked for Tandem Labs/LabCorp/Covance, a bioanalytical contract research organization (CRO), holding various positions from scientist to lab director and technical director. In 2017, Meng moved back to her hometown and set up a bioanalytical CRO, Denali Medpharma, Chongqing, China. In October 2023, Denali was acquired by Resolian Bioanalytics, a global bioanalytical CRO. Currently, Dr Meng is the chief scientific officer and president of the Asia Pacific region for Resolian Bioanalytics | ||
| 650 | 4 | |a Interview | |
| 773 | 0 | 8 | |i Enthalten in |t Bioanalysis |d 2009 |g 16(2024), 2 vom: 01. Jan., Seite 61-64 |w (DE-627)NLM196969840 |x 1757-6199 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2024 |g number:2 |g day:01 |g month:01 |g pages:61-64 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/bio-2023-0216 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2024 |e 2 |b 01 |c 01 |h 61-64 | ||